CCP
BMY icon

Corient Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Corient Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$6.53M Hold
84,777
– – 0.49% 46
2022
Q2 		$6.53M Buy
84,777
+4,709
+6% +$359K 0.49% 48
2022
Q1 		$5.85M Buy
80,068
+7,052
+10% +$474K 0.39% 58
2021
Q4 		$4.55M Buy
73,016
+6,236
+9% +$366K 0.3% 83
2021
Q3 		$3.95M Sell
66,780
-186
-0.3% -$12.2K 0.29% 81
2021
Q2 		$4.47M Sell
66,966
-309
-0.5% -$20.1K 0.33% 72
2021
Q1 		$4.25M Sell
67,275
-50
-0.1% -$3.11K 0.36% 68
2020
Q4 		$4.18M Buy
67,325
+1,478
+2% +$90.9K 0.42% 61
2020
Q3 		$3.97M Buy
65,847
+2,647
+4% +$159K 0.46% 55
2020
Q2 		$3.72M Buy
63,200
+1,952
+3% +$117K 0.45% 55
2020
Q1 		$3.41M Buy
61,248
+5,509
+10% +$337K 0.54% 46
2019
Q4 		$3.58M Buy
55,739
+35,111
+170% +$2.01M 0.45% 53
2019
Q3 		$1.05M Buy
20,628
+8,738
+73% +$411K 0.15% 156
2019
Q2 		$540K Buy
11,890
+2,875
+32% +$134K 0.08% 225
2019
Q1 		$431K Buy
9,015
+127
+1% +$6.33K 0.07% 241
2018
Q4 		$462K Buy
8,888
+3,331
+60% +$179K 0.08% 213
2018
Q3 		$345K Hold
5,557
– – 0.06% 223
2018
Q2 		$307K Buy
5,557
+1,870
+51% +$101K 0.05% 224
2018
Q1 		$233K Sell
3,687
-440
-11% -$28.3K 0.04% 233
2017
Q4 		$253K Sell
4,127
-254
-6% -$15.9K 0.04% 257
2017
Q3 		$279K Sell
4,381
-666
-13% -$38.9K 0.05% 232
2017
Q2 		$281K Sell
5,047
-78
-2% -$4.24K 0.04% 262
2017
Q1 		$279K Sell
5,125
-636
-11% -$34.9K 0.04% 262
2016
Q4 		$337K Sell
5,761
-136
-2% -$7.43K 0.06% 242
2016
Q3 		$318K Buy
+5,897
New +$379K 0.06% 249

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corient Capital Partners's BMY Position: Q3 2022 in Review

Corient Capital Partners held its Bristol-Myers Squibb (BMY) position steady in Q3 2022 at 84,777 shares worth $6.53M. The position accounts for 0.49% of the portfolio, ranked #46.

Corient Capital Partners first reported a position in BMY in Q3 2016 and has held it in 25 quarters since. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

  • Corient Capital Partners held 84,777 shares of Bristol-Myers Squibb worth $6.53M as of Q3 2022.
  • Corient Capital Partners left its Bristol-Myers Squibb share count unchanged in Q3 2022.
  • Bristol-Myers Squibb made up 0.49% of Corient Capital Partners's portfolio in Q3 2022, its #46 holding.
  • Corient Capital Partners first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 25 quarters since.
  • 2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.